Jerry A. Molitor

7.8k total citations · 1 hit paper
28 papers, 2.3k citations indexed

About

Jerry A. Molitor is a scholar working on Pathology and Forensic Medicine, Rheumatology and Immunology. According to data from OpenAlex, Jerry A. Molitor has authored 28 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 9 papers in Rheumatology and 8 papers in Immunology. Recurrent topics in Jerry A. Molitor's work include Systemic Sclerosis and Related Diseases (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and Eosinophilic Disorders and Syndromes (3 papers). Jerry A. Molitor is often cited by papers focused on Systemic Sclerosis and Related Diseases (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers) and Eosinophilic Disorders and Syndromes (3 papers). Jerry A. Molitor collaborates with scholars based in United States, Norway and Austria. Jerry A. Molitor's co-authors include Dean W. Ballard, William H. Walker, Stefan Doerre, W C Greene, Daniel E. Fürst, Christopher H. Goss, Anthony Gerbino, Prakash Sista, Nancy J. Peffer and Ryan T. Demmer and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Jerry A. Molitor

27 papers receiving 2.2k citations

Hit Papers

Sustained benefits of infliximab therapy for dermatologic... 2005 2026 2012 2019 2005 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 502 citations Christian Antoni, Arthur Kavanaugh et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerry A. Molitor United States 18 1.1k 697 573 413 397 28 2.3k
Erika Darrah United States 23 871 0.8× 1.1k 1.6× 300 0.5× 634 1.5× 188 0.5× 62 2.5k
Cristina Teodósio Spain 30 1.7k 1.5× 663 1.0× 391 0.7× 464 1.1× 85 0.2× 77 2.6k
Gisela Orozco United Kingdom 31 1.3k 1.2× 858 1.2× 220 0.4× 764 1.8× 239 0.6× 75 2.6k
Carmen Bellas Spain 22 933 0.8× 388 0.6× 724 1.3× 318 0.8× 96 0.2× 59 1.9k
Rizgar A. Mageed United Kingdom 32 2.0k 1.8× 882 1.3× 312 0.5× 638 1.5× 102 0.3× 112 3.2k
Fabian Flores‐Borja United Kingdom 19 2.2k 1.9× 606 0.9× 225 0.4× 527 1.3× 129 0.3× 34 3.0k
Viktor Roschke United States 16 2.2k 1.9× 1.3k 1.8× 214 0.4× 497 1.2× 197 0.5× 18 3.2k
Stamatis‐Nick C. Liossis Greece 34 1.9k 1.7× 1.5k 2.2× 1.1k 2.0× 802 1.9× 121 0.3× 100 4.0k
H. H. Peter Germany 26 1.4k 1.2× 536 0.8× 167 0.3× 315 0.8× 157 0.4× 64 2.3k
Todd W. Kelley United States 26 622 0.5× 142 0.2× 341 0.6× 707 1.7× 229 0.6× 68 2.0k

Countries citing papers authored by Jerry A. Molitor

Since Specialization
Citations

This map shows the geographic impact of Jerry A. Molitor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry A. Molitor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry A. Molitor more than expected).

Fields of papers citing papers by Jerry A. Molitor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry A. Molitor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry A. Molitor. The network helps show where Jerry A. Molitor may publish in the future.

Co-authorship network of co-authors of Jerry A. Molitor

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry A. Molitor. A scholar is included among the top collaborators of Jerry A. Molitor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry A. Molitor. Jerry A. Molitor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Molitor, Jerry A., et al.. (2024). An Experimental Phototherapy Device for Studying the Effects of Blue Light on Patients with Raynaud’s Phenomenon. Annals of Biomedical Engineering. 52(6). 1732–1743.
2.
Zamanian, Roham T., David B. Badesch, Leland W.K. Chung, et al.. (2021). Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine. 204(2). 209–221. 119 indexed citations
3.
Roan, Florence, Thomas A. Stoklasek, Elizabeth Whalen, et al.. (2016). CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. The Journal of Immunology. 196(5). 2051–2062. 92 indexed citations
4.
5.
Muskardin, Theresa Wampler, B. A. Peterson, & Jerry A. Molitor. (2011). Castleman disease and associated autoimmune disease. Current Opinion in Rheumatology. 24(1). 76–83. 54 indexed citations
6.
Molitor, Jerry A.. (2009). Toward the early diagnosis of systemic sclerosis: warning signs the practitioner needs to recognize.. PubMed. 92(9). 42–4. 4 indexed citations
7.
Wang, Jinnan, Vasily L. Yarnykh, Jerry A. Molitor, et al.. (2008). Micro magnetic resonance angiography of the finger in systemic sclerosis. Lara D. Veeken. 47(8). 1239–1243. 17 indexed citations
8.
9.
Fleming, Jo Nadine, Richard A. Nash, David Fiorentino, et al.. (2008). Correction: Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?. PLoS ONE. 3(8). 8 indexed citations
10.
Fleming, Jo Nadine, David K. Pritchard, Lynn M. Amon, et al.. (2008). Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis & Rheumatism. 58(5). 1465–1474. 102 indexed citations
11.
Fleming, Jo Nadine, Richard A. Nash, David Fiorentino, et al.. (2008). Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?. PLoS ONE. 3(1). e1452–e1452. 146 indexed citations
12.
Kim, Daniel, Deanna M. Santer, Prashant S. Patole, et al.. (2008). Induction of interferon‐α by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon‐α activity with lung fibrosis. Arthritis & Rheumatism. 58(7). 2163–2173. 124 indexed citations
13.
Gerbino, Anthony, Christopher H. Goss, & Jerry A. Molitor. (2007). Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease. CHEST Journal. 133(2). 455–460. 105 indexed citations
14.
Antoni, Christian, Arthur Kavanaugh, Bruce Kirkham, et al.. (2005). Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis & Rheumatism. 52(4). 1227–1236. 502 indexed citations breakdown →
15.
Molitor, Jerry A., et al.. (2005). Resolution of Hypertensive Encephalopathy and Scleroderma Renal Crisis With an Angiotensin Receptor Blocker. JCR Journal of Clinical Rheumatology. 11(4). 205–208. 7 indexed citations
16.
Molitor, Jerry A., Jane H. Buckner, & Gerald T. Nepom. (2002). Transcript array analysis in rheumatology. Rheumatic Disease Clinics of North America. 28(1). 151–176. 1 indexed citations
17.
Molitor, Jerry A., et al.. (1994). Induction of ornithine decarboxylase activity in mouse B lymphocytes. International Immunology. 6(11). 1777–1784. 2 indexed citations
18.
19.
Ballard, Dean W., William H. Walker, Stefan Doerre, et al.. (1990). The v-rel oncogene encodes a κB enhancer binding protein that inhibits NF-κB function. Cell. 63(4). 803–814. 306 indexed citations
20.
Rogers, Keith L., Robert A. Philibert, Albert J. Allen, et al.. (1987). HPLC analysis of putative amino acid neurotransmitters released from primary cerebellar cultures. Journal of Neuroscience Methods. 22(2). 173–179. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Darrah Breakdown of academic impact, for papers by Cristina Teodósio Breakdown of academic impact, for papers by Gisela Orozco Breakdown of academic impact, for papers by Carmen Bellas Breakdown of academic impact, for papers by Rizgar A. Mageed Breakdown of academic impact, for papers by Fabian Flores‐Borja Breakdown of academic impact, for papers by Viktor Roschke Breakdown of academic impact, for papers by Stamatis‐Nick C. Liossis Breakdown of academic impact, for papers by H. H. Peter Breakdown of academic impact, for papers by Todd W. Kelley
Rankless by CCL
2026